18,279 resources
By Version
By Authority
Start Prev Rows 8400 - 8600 Next
| Package | Version | Identity | Name/Title | Status | Date | Auth |
|---|---|---|---|---|---|---|
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.145 | Contraceptive Patch SNOMED Findings | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.146 | Contraceptive Patch ICD10CM Provision Encounters | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.147 | Contraceptive Patch ICD10CM Surveillance | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.148 | Live Birth Delivery ICD10PCS Procedures | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.149 | Contraceptive Patch HCPCS Devices | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.15 | Chlamydia trachomatis and Neisseria Gonorrhoeae combined Tests | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.150 | Contraceptive Patch LOINC | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.152 | Live Birth Delivery Procedures SNOMED CT | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.153 | Contraceptive Ring SNOMED Surveillance Procedures | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.154 | Contraceptive Ring SNOMED Provision Procedures | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.155 | Contraceptive Ring SNOMED Findings | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.156 | Contraceptive Ring ICD10CM Provision Encounters | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.157 | Contraceptive Ring ICD10CM Surveillance | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.159 | Contraceptive Ring HCPCS Devices | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.160 | Contraceptive Ring LOINC | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.161 | Contraceptive Implant SNOMED Devices | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.162 | Contraceptive Implant ICD10PCS Provision Procedures | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.163 | Contraceptive Implant SNOMED Provision Procedures | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.164 | Contraceptive Implant SNOMED Findings | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.170 | Contraceptive Implant ICD10CM Provision Encounters | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.171 | Contraceptive Implant ICD10CM Surveillance | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.173 | Contraceptive Implant HCPCS Devices | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.174 | Contraceptive Patch Devices | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.177 | Live Birth Delivery Procedures | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.178 | Contraceptive Ring Surveillance | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.180 | Contraceptive Implant CPT Provision Procedures | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.181 | Injectable Contraceptive SNOMED Surveillance Procedures | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.182 | Injectable Contraceptive SNOMED Provision Procedures | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.183 | Injectable Contraceptive SNOMED Findings | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.185 | Injectable Contraceptive ICD10CM Provision Encounters | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.186 | Injectable Contraceptive ICD10CM Surveillance | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.187 | Injectable Contraceptive HCPCS Provision Procedures | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.188 | Injectable Contraceptive LOINC | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.189 | Oral Contraceptive Pill SNOMED Surveillance Procedures | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.190 | Oral Contraceptive Pill SNOMED Provision Procedures | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.191 | Oral Contraceptive Pill SNOMED Findings | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.193 | Oral Contraceptive Pill ICD10CM Provision Encounters | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.194 | Oral Contraceptive Pill ICD10CM Surveillance | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.195 | Oral Contraceptive Pill HCPCS Provision Procedures | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.196 | Oral Contraceptive Pill LOINC | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.197 | Injectable Contraceptive Provision Procedures | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.198 | Injectable Contraceptive Surveillance | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.199 | Oral Contraceptive Pill Provision Procedures | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.200 | Oral Contraceptive Pill Surveillance | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.201 | Contraceptive Implant Devices | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.202 | Contraceptive Implant Provision Procedures | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.203 | Contraceptive Implant Surveillance | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.96 | Infecund Not for Contraceptive Reasons SNOMED Findings | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1170.10 | ASN Screening Declined | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1170.2 | Intracranial or Intraspinal surgery | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1170.22 | Emergency Department Observation | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1170.27 | Mental Health Diagnosis without Substance Use Disorders | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1170.28 | Mental Health Diagnosis without Substance Use Disorders | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1170.29 | Bed Assigned | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1170.3 | Malignant Intracranial Neoplasm Group | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1170.31 | Healthcare Agent & Power of Attorney Documentation | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1170.32 | Healthcare Agent and Power of Attorney Documentation | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1170.33 | Advance Directive Documentation | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1170.34 | Advance Directive Documentation | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1170.35 | Advance Directive Documentation | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1170.36 | Portable Medical Order(s) Documentation | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1170.37 | Portable Medical Order(s) Documentation | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1170.38 | Advance Care Planning Discussion Documentation | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1170.4 | Thrombolytic medications | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1170.40 | Advance Care Planning Documentation | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1170.41 | Advance Care Planning Documentation | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1170.42 | Healthcare Agent & Power of Attorney Documentation | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1170.43 | Advance Directive Documentation | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1170.45 | Advance Care Planning Documentation | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1170.46 | Advance Care Planning Documentation | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1170.47 | Portable Medical Order(s) Documentation | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1170.48 | Portable Medical Order(s) Documentation | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1170.49 | Intervention for Positive Utility Insecurity Screen | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1170.5 | Allergy to thrombolytics | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1170.50 | Intervention for Positive Utility Insecurity Screen | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1170.51 | Intervention for Positive Transportation Insecurity Screen | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1170.52 | Intervention for Positive Transportation Insecurity Screen | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1170.53 | Intervention for Positive Housing Instability Screen | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1170.54 | Intervention for Positive Housing Instability Screen | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1170.55 | Intervention for Positive Homelessness Screen | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1170.56 | Intervention for Positive Homelessness Screen | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1170.57 | Non Invasive Oxygen Therapy Device Codes | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1170.58 | Goals, preferences, and priorities for medical treatment | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1170.6 | Thrombolytics Adverse Event | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1170.7 | Intraspinal surgery | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1176.58 | Food Insecurity Screening Positive | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.1 | Ezetimibe Therapy | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.10 | Antihypertensive Medications | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.100 | Allergy or Intolerance to ACE Medication | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.101 | Allergy or Intolerance to ARB Medication | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.102 | Chronic Kidney Disease Stage 1 | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.103 | Chronic Kidney Disease Stage 2 | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.104 | Chronic Kidney Disease Stage 3 | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.105 | Chronic Kidney Disease Stage 4 | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.106 | Chronic Kidney Disease Stage 5 | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.107 | ICD10 CM Chronic Kidney Disease Stage 1 | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.108 | ICD10 CM Chronic Kidney Disease Stage 2 | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.111 | AHA GWTG Chronic Kidney Disease Stage 2 | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.112 | ICD10 CM Chronic Kidney Disease Stage 3 | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.113 | ICD10 CM Chronic Kidney Disease Stage 4 | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.114 | ICD10 CM Chronic Kidney Disease Stage 5 | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.115 | AHA GWTG Chronic Kidney Disease Stage 1 | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.116 | AHA GWTG Chronic Kidney Disease Stage 3 | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.117 | AHA GWTG Chronic Kidney Disease Stage 4 | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.118 | SNOMED CT Atrial Fibrillation | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.119 | ICD10 CM Atrial Fibrillation | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.121 | AHA GWTG Atrial Fibrillation | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.123 | SNOMED CT Hyperlipidemia | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.124 | ICD10 CM Hyperlipidemia | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.125 | AHA GWTG Hyperlipidemia | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.126 | SNOMED CT Hypertriglyceridemia | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.127 | ICD10 CM Hypertriglyceridemia | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.129 | AHA GWTG Hypertriglyceridemia | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.130 | SNOMED CT Gestational Diabetes | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.131 | ICD10 CM Gestational Diabetes | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.132 | AHA GWTG Gestational Diabetes | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.133 | SNOMED CT Hyperglycemia | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.134 | ICD10 CM Hyperglycemia | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.135 | AHA GWTG Hyperglycemia | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.136 | SNOMED CT Nonobstructive CAD | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.137 | ICD10 CM Nonobstructive Coronary Artery Disease | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.138 | AHA GWTG Nonobstructive coronary artery disease | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.139 | AHA GWTG Anti Obesity Pharmacotherapy | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.15 | Non Tobacco Smoking Product User | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.16 | Antihypertensive Fixed Dose Combination Medications | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.2 | PCSK9 Inhibitors | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.20 | CCB and Thiazide and Thiazide Like Diuretics | active | 2021-01 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.21 | Referral to cardiac rehab | active | 2021-04 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.22 | Cardiac Rehabilitation | active | 2021-04 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.25 | 2 Hour Blood Glucose Test | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.26 | NYHA Functional Classification | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.27 | ARNI Therapy | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.29 | MRA Therapy | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.3 | Cholesterol non HDL Laboratory Test | active | 2021-04 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.30 | SGLT2 Inhibitors | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.31 | Heart Transplant | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.32 | Heart Transplant | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.33 | Heart Transplant | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.34 | Allergy to MRA Therapy | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.35 | Aspirin or Clopidogrel | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.39 | Cardiac Rehabilitation | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.4 | Hypothyroidism | active | 2021-04 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.40 | Cardiac Rehabilitation | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.43 | SGLT2 Ingredients | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.44 | MRA Ingredients | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.49 | Minnesota Living with Heart Failure Questionnaire | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.5 | Hypothyroidism | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.50 | Kansas City Cardiomyopathy Questionnaire | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.51 | Cardiac Pacer | active | 2021-11 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.52 | Cardiac Pacer | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.53 | Cardiac Pacer | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.54 | Heart Transplant Complications | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.55 | Heart Transplant Complications | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.56 | Heart Transplant Complications | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.57 | Left Ventricular Assist Device Complications | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.58 | Left Ventricular Assist Device Complications | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.59 | Left Ventricular Assist Device Placement | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.6 | Hypothyroidism | active | 2021-04 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.60 | Left Ventricular Assist Device Placement | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.61 | Left Ventricular Assist Device Placement | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.62 | Left Ventricular Assist Device Placement | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.63 | Heart Transplant | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.65 | Cardiac Pacer | active | 2022-11 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.66 | Diastolic Heart Failure | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.67 | Diastolic Heart Failure | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.68 | Diastolic Heart Failure | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.69 | Allergy to SGLT2 Inhibitors | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.7 | Anorexia Nervosa | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.70 | Intolerance to SGLT2 Inhibitors | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.71 | Intolerance to MRA Therapy | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.72 | ARNI Ingredient | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.73 | Mitral Stenosis | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.74 | Mitral Stenosis | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.75 | Mitral Stenosis | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.76 | Mechanical Prosthetic Heart Valve | active | 2022-11 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.77 | Mechanical Prosthetic Heart Valve | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.78 | Mechanical Prosthetic Heart Valve | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.79 | Mechanical Prosthetic Heart Valve in Situ | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.8 | Anorexia Nervosa | active | 2021-04 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.82 | Systolic Heart Failure | active | 2023-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.83 | Systolic Heart Failure | active | 2023-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.84 | Systolic Heart Failure | active | 2023-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.85 | Carotid Intervention | active | 2023-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.86 | Serum Creatinine | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.87 | Urine Creatinine | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.88 | Urine Albumin | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.9 | Anorexia Nervosa | active | 2021-04 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.90 | Non Steroidal Mineralcorticoid Receptor Antagonist | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.91 | Glucagon like peptide 1 medications | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.96 | AHA GWTG Long COVID19 | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1181.1 | Wound internal item and/or body structure visible value set (foundation metadata concept) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1181.11 | Wound exudate appearance value set (foundation metadata concept) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1181.12 | Wound exudate color value set (foundation metadata concept) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1181.13 | Exudate odor value set (foundation metadata concept) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1181.16 | Skin temperature value set (foundation metadata concept) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1181.17 | Skin color enumerated value set (foundation metadata concept) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1181.18 | Skin turgor value set (foundation metadata concept) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1181.19 | Skin and mucous membrane integrity value set (foundation metadata concept) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1181.2 | Periwound condition value set (foundation metadata concept) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1181.20 | Skin moisture value set (foundation metadata concept) | active | 2024-06 | hl7 |
FHIR